Oxidant-antioxidant	JJ
imbalance	NN
as	IN
a	DT
potential	JJ
contributor	NN
to	TO
the	DT
progression	NN
of	IN
human	JJ
pulmonary	JJ
fibrosis	NN
.	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
the	DT
most	RBS
common	JJ
idiopathic	JJ
interstitial	JJ
pneumonia	NN
.	.

IPF	NN
is	VBZ
a	DT
disease	NN
with	IN
poor	JJ
prognosis	NN
and	CC
an	DT
aggressive	JJ
nature	NN
,	,
and	CC
poses	VBZ
major	JJ
challenges	NNS
to	TO
clinicians	NNS
.	.

Thus	RB
,	,
a	DT
large	JJ
part	NN
of	IN
research	NN
in	IN
the	DT
area	NN
has	VBZ
focused	VBN
on	IN
the	DT
pathogenesis	NN
on	IN
IPF	NN
.	.

Characteristic	JJ
features	NNS
in	IN
IPF	NN
include	VBP
fibrotic	JJ
lesions	NNS
devoid	JJ
of	IN
inflammatory	JJ
cell	NN
infiltrates	NNS
.	.

There	EX
are	VBP
experimental	JJ
models	NNS
of	IN
lung	NN
fibrosis	NN
(	(
e.g.	FW
,	,
bleomycin-induced	JJ
fibrosis	NN
)	)
,	,
but	CC
they	PRP
typically	RB
contain	VBP
a	DT
prominent	JJ
inflammatory	JJ
pattern	NN
in	IN
the	DT
lung	NN
,	,
which	WDT
leads	VBZ
to	TO
relatively	RB
diffuse	JJ
lung	NN
fibrosis	NN
.	.

Nonetheless	RB
,	,
experimental	JJ
models	NNS
have	VBP
provided	VBN
important	JJ
information	NN
about	IN
the	DT
progression	NN
and	CC
pathways	NNS
contributing	VBG
to	TO
the	DT
lung	NN
fibrosis	NN
,	,
including	VBG
activation	NN
of	IN
transforming-growth-factor-beta	NN
(	(
TGF-beta	NN
)	)
.	.

Both	DT
patient	NN
material	NN
and	CC
experimental	JJ
models	NNS
of	IN
lung	NN
fibrosis	NN
have	VBP
displayed	VBN
marked	JJ
elevation	NN
of	IN
several	JJ
markers	NNS
of	IN
oxidant	JJ
burden	NN
and	CC
signs	NNS
for	IN
disturbed	JJ
antioxidant/oxidant	JJ
balance	NN
.	.

Several	JJ
studies	NNS
also	RB
suggest	VBP
that	IN
reactive	JJ
oxygen	NN
species	NNS
can	MD
cause	VB
activation	NN
of	IN
growth-regulatory	JJ
cytokines	NNS
,	,
including	VBG
TGF-beta	NN
.	.

In	IN
addition	NN
,	,
there	EX
are	VBP
indications	NNS
that	WDT
endogenous	JJ
and	CC
exogenous	JJ
antioxidants/redox	JJ
modulators	NNS
can	MD
influence	VB
fibrogenesis	NN
,	,
protect	VBP
the	DT
lung	NN
against	IN
fibrosis	NN
,	,
and	CC
prevent	VB
its	PRP$
progression	NN
.	.

Factors	NNS
that	WDT
restore	VBP
the	DT
antioxidant	JJ
capacity	NN
and	CC
prevent	VB
sustained	JJ
activation	NN
of	IN
growth-regulatory	JJ
cytokines	NNS
may	MD
have	VB
a	DT
therapeutic	JJ
role	NN
in	IN
IPF	NN
.	.

